Navigation Links
BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
Date:5/28/2013

RALEIGH, N.C., May 28, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo , President and Chief Executive Officer of BDSI, will present at the Jefferies 2013 Global Healthcare Conference.  The presentation is scheduled for Tuesday, June 4, 2013 at 8:30 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Dr. Sirgo will provide an update on the status of the upcoming New Drug Application (NDA) submission and market opportunity for BUNAVAIL for the treatment of opioid dependence. Additionally, Dr. Sirgo will discuss progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain, along with BDSI's recent licensing of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

BDSI's pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). 

BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy, which was recently licensed from Arcion Therapeutics.

Additionally, BDSI is developing BUNAVAIL, a high dose formulation of buprenorphine in combination with naloxone for the treatment of opioid dependence.  Both BEMA Buprenorphine and BUNAVAIL are in Phase 3 clinical development, and Clonodine Topical Gel is in Phase 2 clinical development. 

BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentation referred to herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  All other trademarks and tradenames are owned by their respective owners.

© BioDelivery Sciences International, Inc.  All rights reserved.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
4. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
5. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
6. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
7. BioDelivery Sciences Announces Completion of BNX Safety Study
8. BioDelivery Sciences Announces $40 Million Registered Financing
9. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
10. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
11. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 Eye expert s ... babies to seek an eye examination ...   Moorfields Eye Hospital Dubai, the first ... London , has identified premature babies as a special concern ... their particular vulnerability to retinopathy of prematurity (ROP). ROP is a ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two ... their patients from other participating organizations in the exchange. SJMC’s membership in the ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's ... advertising campaigns, to monitor the performance of sales and support staff, and to ... revenue. The software allows customers to record, transcribe, route, document, and report on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Dr. Charles A. ... Dentistry of New Jersey in the class of 1986, where he graduated in the ... at his current location in Livingston since 1989. He has been a member in ...
Breaking Medicine News(10 mins):